General Information of Drug (ID: DMRBKW6)

Drug Name
PD173212 Drug Info
Synonyms
PD 173212; 217171-01-2; PD173212; CHEMBL299749; N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-(phenylmethyl)-L-Tyrosinamide; SCHEMBL8188148; DTXSID10432752; MolPort-006-822-718; ZINC3941150; BDBM50078723; ABP000999; AKOS024457680; CS-7879; NCGC00347242-02; DB-066610; HY-103318; B7424; FT-0773764; J-014254; N-[[4-(1,1-Dimethylethyl)phenyl]methyl-N-methyl-L-leucyl-N-(1,1-dimethylethyl)-O-phenylmethyl)-L-tyrosinamide; (S)-2-[(4-tert-Butyl-benzyl)-methyl-amino]-4-methyl-pentanoic acid [(S)-2-(4-
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Investigative [1]
Therapeutic Class
Analgesics
Cross-matching ID
PubChem CID
9916734
CAS Number
CAS 217171-01-2
TTD Drug ID
DMRBKW6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nifedipine DMSVOZT Angina pectoris BA40 Approved [2]
Clevidipine butyrate DMW4M97 Hypertension BA00-BA04 Approved [3]
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [1]
Otilonium bromide DM05968 Gastric motility disorder DA21 Approved [4]
Levamlodipine DM92S6N Hypertension BA00-BA04 Phase 4 [5]
Cilnidipine DM1975O High blood pressure BA00 Phase 3 [6]
Pinaverium bromide DM7OSHC Irritable bowel syndrome DD91.0 Phase 3 [4]
MEM-1003 DMYZU6G Bipolar disorder 6A60 Phase 2a [7]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [8]
BAY-Y-5959 DMLO18H Cardiovascular disease BA00-BE2Z Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated L-type calcium channel (L-CaC) TTXHYV6 NOUNIPROTAC Blocker [1]

References

1 Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
5 Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
6 N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
7 Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
8 Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
9 Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.